NEW YORK, Oct. 9 - Genaissance Pharmaceuticals has licensed certain data from its haplotype library to drug giant Pfizer, Genaissance said on Tuesday.
Financial terms of the deal were not disclosed.
Genaissance, based in New Haven, Conn., has already identified roughly 80,000 haplotypes from almost 5,000 genes and says it intends to discover haplotypes across the entire genome.
“This [deal] is an indication that major pharmaceutical companies are moving to adopt haplotype technology to help accelerate the development of new medicines,” Genaissance CEO Gualberto Ruano said in a statement.
As GenomeWeb reported, Genaissance Pharmaceuticals in April started enrolling patients for clinical trials designed to help the company learn what haplotypes are related to an individual’s response to particular drugs.
In this initial study, which will last about a year, Genaissance will study about 600 patients at 60 medical centers in the US to correlate their haplotypes with the affects of certain cholesterol-lowering drugs, including Pfizer’s Lipitor, Merck’s Zocor, Bristol-Myers Squibb’s Pravachol, and Bayer’s Baycol. Bayer, however, withdrew Baycol from the market in August after the drug was linked to 52 patient deaths in the US and Europe.